GLP-1 Drugs Linked to Ulcerative Colitis Remission
A real-world study of 300 patients found those taking GLP-1 drugs liraglutide or semaglutide had significantly higher remission rates at 12 weeks compared to controls, suggesting a direct anti-inflammatory effect.
Patients with ulcerative colitis who took GLP-1 receptor agonists saw significantly higher rates of disease control than those who did not, according to a new retrospective study. The research, led by Budoor Alqinai, MBChB, MSc, of West Virginia University, analyzed data from 300 patients and suggests these diabetes and weight-loss drugs may have a direct anti-inflammatory effect on the bowel.
Study Findings on Disease Control Rates
The study compared 150 patients prescribed either liraglutide (sold as Victoza and Saxenda) or semaglutide (sold as Ozempic and Wegovy) to a matched control group of 150 patients not on a GLP-1 drug. Symptomatic disease control, defined by a specific low score on a disease activity index, was assessed over 12 weeks. The rates of symptom resolution for the GLP-1 group were markedly higher at every checkpoint.
| Time Point | GLP-1 User Disease Control Rate | Control Group Disease Control Rate |
|---|---|---|
| 4 weeks | 34.7% | 15.3% |
| 8 weeks | 54.7% | 18% |
| 12 weeks | 66.7% | 25.3% |
After adjusting for factors like age, disease severity, and other treatments, using a GLP-1 drug was strongly and independently associated with achieving a low disease state. The researchers published their findings in the journal Inflammatory Bowel Diseases.
Semaglutide Shows Modest Advantage
When comparing the two drugs studied, semaglutide showed a modest benefit over liraglutide. At the 12-week mark, 72.5% of patients on semaglutide achieved symptomatic disease control, compared to 60% of those on liraglutide. The study authors noted this difference was statistically significant.
A key observation was that clinical improvement in colitis symptoms appeared before patients experienced substantial weight loss. This timing supports the hypothesis that the drugs' benefit may work through a weight-independent, anti-inflammatory mechanism. "Notably, clinical improvement preceded meaningful weight loss," Alqinai's team wrote.
Endoscopic Results and Safety Profile
An exploratory analysis looked at a subset of patients who underwent a follow-up colonoscopy. It found that 58% of GLP-1 users achieved endoscopic healing, meaning visible repair of the intestinal lining, compared to 38% of controls. Improvements in the endoscopic appearance were seen in 69% of drug users versus 47% of non-users.
The drugs were generally well-tolerated. Common side effects were gastrointestinal, including transient nausea in about 30% of patients and occasional vomiting in 10%. No patient discontinued the drugs due to side effects during the 12-week study, and no ulcerative colitis-specific adverse events were linked to GLP-1 use.
Weight Loss Not a Primary Driver
Patients on GLP-1 drugs lost an average of 8.2% of their body weight over 12 weeks, which aligns with the known effects of these medications. However, a detailed statistical analysis confirmed that the degree of weight loss was not independently linked to achieving a controlled disease state. This further bolsters the theory of a separate, direct anti-inflammatory action.
The authors caution that while these real-world findings are promising, confirmation from prospective, randomized controlled trials is necessary. The study's retrospective design means that despite careful matching of patient groups, some unseen factors could influence the results. These findings add to a growing body of research hinting that GLP-1 drugs might have therapeutic benefits for inflammatory bowel diseases that extend beyond their original metabolic purposes.
